Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply-Reference-Cited by-同舟云学术

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Published:2024-07-03 Issue:4 Volume:60 Page:542-543
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Scheiner Bernhard¹²^ORCID,Dominik Nina¹²^ORCID,Mandorfer Mattias¹²^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria

2. Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III Medical University of Vienna Vienna Austria

Abstract

LINKED CONTENTThis article is linked to Dominik et al papers. To view these articles, visit https://doi.org/10.1111/apt.17945 and https://doi.org/10.1111/apt.18066

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18144

Reference10 articles.

1. Letter: helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease;Kountouras J;Aliment Pharmacol Ther,2024

2. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

3. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD

4. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia

5. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis